Event registration | PRIME Oncology

Letrozole Therapy Alone or in Sequence with Tamoxifen: Practical Clinical Implications of the BIG 1.98 Trial

Expert Perspectives with Henning Mouridsen, MD, PhD
Interview conducted by Joseph Gligorov, MD

Henning Mouridsen, MD, PhD, is interviewed on the publication of the results of the BIG 1.98 trial and how these results may affect clinical practice.

This independent medical education activity is one of a series of Live Expert Interviews held in conjunction with major medical publication releases to provide critical clinical information in the field of breast cancer.

Henning Mouridsen, MD, PhD
Copenhagen University Hospital
Copenhagen, Denmark

Joseph Gligorov, MD
Tenon University Hospital
Paris, France

Disclaimer: The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indication where you practice.

This Webcast is available from 30 October 2009 to 30 October 2010.

This activity is supported by a grant from Novartis Oncology.

Please enter your Email address and click "Next" to proceed to the next page.

If your Email address is found in our system, we will retrieve your information for verification,
if not, we will ask you to fill out registration form.